TrialAllergy2019

Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.

Karin Jonstam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.